IAS 3 Rio de Janeiro 2005

Further Reports from 3rd IAS Conference on AIDS Pathogenesis and Treatment, Rio de Janeiro, Brazil, 24-27 July 2005

Management of hepatitis C and B in HIV-coinfected individuals: an overview of studies presented at the 3rd IAS Conference

Highlights of HIV drug resistance studies presented at the 3rd IAS Conference

3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005, Rio de Janeiro, Brasil

Adult male circumcision reduces transmission rates over 18 months comparable to a vaccine with 65% efficacy

Benefits of adding 4 or 7 days of AZT/3TC to single-dose nevirapine to prevent MTCT: further analysis from TOPS

New drugs in pregnancy: atazanavir; T20

Lopinavir/r use in children less than two years old – promising results despite low plasma levels

Favourable outcomes in children treated with HAART in the MSF programmes

Encouraging results with cut up generic fixed dose combination tablets in Uganda

Predictors of survival at three years follow up for HIV-infected children in Cote D’Ivoire

Benefit of maintaining the M184V mutation with 3TC monotherapy: final 48-week results

T20 (enfuvirtide) studies presented at Rio

Strategies for salvage therapy

Antiviral activity of foscarnet in salvage patients

Novel strategies with existing drugs

Antiretroviral activity of new and novel agents

Overview of pharmacology studies

Incidence of TB infection despite HAART and treatment in coinfected patients

Evaluation of ESAT-6 and CFP-10 as markers for response to TB treatment in HIV/TB coinfected patients

Does WHO clinical stage reliably predict who should receive ARV treatment?

Continuous vs intermittent treatment with triple nuke combination of AZT/3TC/tenofovir in Africa: early results from DART study